CX3CL1/CX3CR1 Axis Contributes to Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation and Inflammatory Cytokine Production

Overview

Journal Inflammation

Specialties Allergy & Immunology
Pathology

Date 2018 Jan 23

PMID 29356931

Citations 12

Authors

Chengsheng Li

Jin He

Xiaoyi Zhong

Hua Gan

Yunfeng Xia

Affiliations

Soon will be listed here.

Abstract

Angiotensin II (Ang II) dysregulation has been determined in many diseases. The CX3CL1/CX3CR1 axis, which has a key role in cardiovascular diseases, is involved in the proliferation and inflammatory cytokine production of vascular smooth muscle cells (VSMCs). In this study, we aim to explore whether Ang II has a role in the expression of CX3CL1/CX3CR1, thus contributing to the proliferation and pro-inflammatory status of VSMCs. Cultured mouse aortic VSMCs were stimulated with 100 nmol/L of Ang II, and the expression of CX3CR1 was assessed by western blot. The results demonstrated that Ang II significantly up-regulated CX3CR1 expression in VSMCs and induced the production of reactive oxygen species (ROS) and the phosphorylation of p38 MAPK. Inhibitors of NADPH oxidase, ROS, and AT1 receptor significantly reduced Ang II-induced CX3CR1 expression. Targeted disruption of CX3CR1 by transfection with siRNA significantly attenuated Ang II-induced VSMC proliferation as well as down-regulated the expression of proliferating cell nuclear antigen (PCNA). Furthermore, CX3CR1-siRNA suppressed the effect of Ang II on stimulating Akt phosphorylation. Besides, the use of CX3CR1-siRNA decreased inflammatory cytokine production induced by Ang II treatment. Our results indicate that Ang II up-regulates CX3CR1 expression in VSMCs via NADPH oxidase/ROS/p38 MAPK pathway and that CX3CL1/CX3CR1 axis contributes to the proliferative and pro-inflammatory effects of Ang II in VSMCs.

Citing Articles

The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.

Hsu R, Yu W, Peng G, Ye C, Hu S, Chong P Front Immunol. 2022; 13:832394.

PMID: 35464491 PMC: 9021400. DOI: 10.3389/fimmu.2022.832394.

CX3CR1 Acts as a Protective Biomarker in the Tumor Microenvironment of Colorectal Cancer.

Yue Y, Zhang Q, Sun Z Front Immunol. 2022; 12:758040.

PMID: 35140706 PMC: 8818863. DOI: 10.3389/fimmu.2021.758040.

Host factors: Implications in immunopathogenesis of COVID-19.

Jafarpour R, Pashangzadeh S, Dowran R Pathol Res Pract. 2021; 228:153647.

PMID: 34749207 PMC: 8505027. DOI: 10.1016/j.prp.2021.153647.

Analysis of lncRNA-miRNA-mRNA expression pattern in heart tissue after total body radiation in a mouse model.

Aryankalayil M, Martello S, Bylicky M, Chopra S, May J, Shankardass A J Transl Med. 2021; 19(1):336.

PMID: 34364390 PMC: 8349067. DOI: 10.1186/s12967-021-02998-w.

Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia.

Chamera K, Szuster-Gluszczak M, Basta-Kaim A Pharmacol Rep. 2021; 73(4):1063-1078.

PMID: 34021899 PMC: 8413165. DOI: 10.1007/s43440-021-00269-5.

References

Montezano A, Nguyen Dinh Cat A, Rios F, Touyz R . Angiotensin II and vascular injury. Curr Hypertens Rep. 2014; 16(6):431. DOI: 10.1007/s11906-014-0431-2. View

Yang X, Mattagajasingh S, Su S, Chen G, Cai Z, Fox-Talbot K . Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway. Circ Res. 2007; 101(10):1001-8. DOI: 10.1161/CIRCRESAHA.107.160812. View

Ikejima H, Imanishi T, Tsujioka H, Kashiwagi M, Kuroi A, Tanimoto T . Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J. 2009; 74(2):337-45. DOI: 10.1253/circj.cj-09-0484. View

Hendrik Niess J, Adler G . Enteric flora expands gut lamina propria CX3CR1+ dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions. J Immunol. 2010; 184(4):2026-37. DOI: 10.4049/jimmunol.0901936. View

Sun H, Liu T, Zhang F, Xiong X, Wang J, Chen Q . Salusin-β contributes to vascular remodeling associated with hypertension via promoting vascular smooth muscle cell proliferation and vascular fibrosis. Biochim Biophys Acta. 2015; 1852(9):1709-18. DOI: 10.1016/j.bbadis.2015.05.008. View

Kasal D, Schiffrin E . Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities. Int J Hypertens. 2012; 2012:829786. PMC: 3364573. DOI: 10.1155/2012/829786. View

Xi X, Graf K, Goetze S, Fleck E, Hsueh W, Law R . Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999; 19(1):73-82. DOI: 10.1161/01.atv.19.1.73. View

Touyz R, Schiffrin E . Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000; 52(4):639-72. View

Chiou W, Chen C, Wei B . 3,4-Di-O-Caffeoylquinic Acid Inhibits Angiotensin-II-Induced Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating the JNK and PI3K/Akt Signaling Pathways. Evid Based Complement Alternat Med. 2009; 2011:634502. PMC: 3136752. DOI: 10.1093/ecam/nep140. View

10.

Gan A, Butoi E, Manea A, Simion V, Stan D, Parvulescu M . Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways. Cell Tissue Res. 2012; 351(1):161-74. DOI: 10.1007/s00441-012-1510-9. View

11.

Zheng L, Cao Y, Liu S, Peng Z, Zhang S . Neferine inhibits angiotensin II-induced rat aortic smooth muscle cell proliferation predominantly by downregulating fractalkine gene expression. Exp Ther Med. 2014; 8(5):1545-1550. PMC: 4186444. DOI: 10.3892/etm.2014.1952. View

12.

Koziolek M, Muller G, Zapf A, Patschan D, Schmid H, Cohen C . Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure. Nephrol Dial Transplant. 2009; 25(3):684-98. DOI: 10.1093/ndt/gfp602. View

13.

Mizutani N, Sakurai T, Shibata T, Uchida K, Fujita J, Kawashima R . Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine. J Immunol. 2007; 179(11):7478-87. DOI: 10.4049/jimmunol.179.11.7478. View

14.

Chandrasekar B, Mummidi S, Perla R, Bysani S, Dulin N, Liu F . Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J. 2003; 373(Pt 2):547-58. PMC: 1223517. DOI: 10.1042/BJ20030207. View

15.

Moatti D, Faure S, Fumeron F, Seknadji P, McDermott D, Debre P . Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001; 97(7):1925-8. DOI: 10.1182/blood.v97.7.1925. View

16.

Zhang F, Ren X, Zhao M, Zhou B, Han Y . Angiotensin-(1-7) abrogates angiotensin II-induced proliferation, migration and inflammation in VSMCs through inactivation of ROS-mediated PI3K/Akt and MAPK/ERK signaling pathways. Sci Rep. 2016; 6:34621. PMC: 5043354. DOI: 10.1038/srep34621. View

17.

Ludwig A, Berkhout T, Moores K, Groot P, Chapman G . Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol. 2002; 168(2):604-12. DOI: 10.4049/jimmunol.168.2.604. View

18.

Ragolia L, Palaia T, Paric E, Maesaka J . Prostaglandin D2 synthase inhibits the exaggerated growth phenotype of spontaneously hypertensive rat vascular smooth muscle cells. J Biol Chem. 2003; 278(24):22175-81. DOI: 10.1074/jbc.M302769200. View

19.

Cai H, Griendling K, Harrison D . The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003; 24(9):471-8. DOI: 10.1016/S0165-6147(03)00233-5. View

20.

Butoi E, Gan A, Manduteanu I, Stan D, Calin M, Pirvulescu M . Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta. 2011; 1813(12):2026-35. DOI: 10.1016/j.bbamcr.2011.08.009. View